Cytomegalovirus and Death in Liver Transplantation
Authors: Nina Singh
Journal: Annals of Internal Medicine (1997)

Letters1 September 1997Cytomegalovirus and Death in Liver TransplantationNina Singh, MD and Timothy Gayowski, MDNina Singh, MDVeterans Affairs Medical Center; Pittsburgh, PA 15240Search for more papers by this author and Timothy Gayowski, MDVeterans Affairs Medical Center; Pittsburgh, PA 15240Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-5-199709010-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Falagas and colleagues [1] concluded that the cytomegalovirus (CMV) serologic status of liver transplant donors and recipients was a significant determinant of death in the recipients. Our experience differs substantially from theirs. In our program, 130 patients have undergone orthotopic liver transplantation under tacrolimus-based primary immunosuppression in the 1990s. Neither CMV infection nor disease were predictors of death in our patients [2], and no correlation between the CMV serostatus of recipients and donors and death was seen (Table 1).Table 1. 1-Year Mortality Rates in Liver Transplant Recipients, Stratified by Donor and Recipient Cytomegalovirus Serologic Status Table ...References1. Falagas MD, Snydman DR, Griffith J, Ruthazer R, Werner BG, et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med. 1997; 126:275-9. Google Scholar2. Gayowski T, Marino IR, Singh N, Doyle HR, Wagener MM, Fung JJ, et al. Risk factors associated with mortality and infectious morbidity after liver transplantation [Abstract]. Annual Meeting of the American Association of the Study of Liver Diseases. Chicago; 1996. Google Scholar3. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. European FK506 Multicenter Liver Study Group. Lancet. 1994; 344:423-8. Google Scholar4. Singh N, Mieles L, Yu VL, Starzl TE. Decreased incidence of viral infections in liver transplant recipients: possible effects of FK506. Dig Dis Sci. 1994; 39:15-8. Google Scholar5. Stratta RJ, Shaeffer MS, Markin RS, Wood RP, Langnas AN, et al. Cytomegalovirus infection and disease after liver transplantation: an overview. Dig Dis Sci. 1992; 37:673-88. Google Scholar Author, Article, and Disclosure InformationAffiliations: Veterans Affairs Medical Center; Pittsburgh, PA 15240 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trialsInfección precoz en el paciente con trasplante hepático: incidencia, gravedad, factores de riesgo y sensibilidad antibiótica de los aislados bacterianos 1 September 1997Volume 127, Issue 5Page: 412KeywordsCytomegalovirus infectionDeath ratesInfectious diseasesLiver transplantationMortalityOrthotopic liver transplantationTransplantation Issue Published: 1 September 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...